阳离子脂质体介导HSV-TK/ACV基因系统抑制人肺癌生长的实验研究

Experimental Study of HSV-TK/ACV Transfected by Cationic Liposome to Treat Lung Cancer Cell

目的:探讨阳离子脂质体介导的HSV-TK/ACV基因系统治疗人肺癌的实验研究的意义。方法:利用已构建的真核表达质粒pCR3-TK,用阳离子脂质体LipofectAMINE为载体,将pCR3-TK转染Anip973细胞株,然后给予不同浓度的Aciclovir(ACV)。结果:经MTT检测证实转染了TK基因的肺癌细胞对ACV的杀伤敏感性明显提高,FCM检测可以看到凋亡峰的出现,且相应的S期细胞比率增高。结论:HSV-TK/ACV系统对人类肺癌细胞株Anip973具有良好的抑制作用;阳离子脂质体LipofectAMINE对人类肺癌细胞株Anip973安全、低毒,有可能成为基因治疗应用到临床试验的有价值的载体。

Objective: To investigate the experimental value of HSV-TK/ACV transfected by cationic liposome to treat human lung cancer cell. Methods: With the cationic lipofectAMINE, we transfect the eukaryotic expressing liposome pCR3-TK, which was constructed before, to human lung cancer cell line Anip973, and then different concentration Aciclovir (ACV) was administrated. Results: MTT confirmed the increasing sensitivity level of TK gene-transfected lung cancer cells to ACV. FCM showed apoptosis and S phase blocking had occurred in the cell lines transfected with pCR3-TK. Conclusion: The results indicate that HSV-TK/ACV system is a promising gene therapy approach for the human lung cancer cell line Anip973 and the cationic liposome is a safe vector for gene transfection.